Oxurion’s plasma kallikrein inhibitor shows positive phase 1 study results

Phase 1 study results for THR-149, Oxurion’s plasma kallikrein inhibitor, showed it to be safe and well tolerated with a rapid onset of action from the first day of treatment in patients with diabetic macular edema, according to a press release.
The open-label, multicenter, non-randomized trial evaluated a single intravitreal injection of THR-149 at three ascending dose levels in 12 patients. After 14 days, the average best corrected visual acuity improved up to 7.5 letters, with an average BCVA improvement of 6.5 letters at day 90, the release said.
“These (Read more...)

Full Story →